中国医院用药评价与分析2023，Vol.23Issue(12)：1496-1498,1503,4.DOI:10.14009/j.issn.1672-2124.2023.12.017
吲哚布芬联合替格瑞洛对比阿司匹林联合替格瑞洛用于经皮冠状动脉介入治疗术后的成本-效用分析
Cost-Effectiveness Analysis of Indobufen Combined with Ticagrelor Versus Aspirin Combined with Ticagrelor for Post-Percutaneous Coronary Intervention Therapy
摘要
Abstract
OBJECTIVE:To evaluate the cost-effectiveness of indobufen combined with ticagrelor versus aspirin combined with ticagrelor for antiplatelet therapy after percutaneous coronary intervention(PCI).METHODS:Markov model was used to simulate the economic outcomes of patients treated with indobufen + ticagrelor and aspirin + ticagrelor for antiplatelet therapy after PCI.Quality-adjusted life years(QALY)was set as the effectiveness measure,the total costs,total effectiveness and incremental cost-effectiveness ratios(ICER)of two treatment regimens were calculated.RESULTS:Over a 10-year time horizon,the total cost of indobufen + ticagrelor was 172 292.28 yuan,while the total cost of aspirin + ticagrelor was 169 950.51 yuan.The QALY gained with indobufen + ticagrelor and aspirin + ticagrelor were 6.540 and 6.335,respectively.The ICER of indobufen + ticagrelor to aspirin + ticagrelor was 11 472.09 yuan/QALY,lower than per capita GDP in China.These results suggested that indobufen+ticagrelor is significantly better than aspirin+ticagrelor in cost-effectiveness.Sensitivity analysis demonstrated that the results of the study were robust and reliable.CONCLUSIONS:Results of the study indicate that indobufen + ticagrelor is more cost-effectiveness than aspirin + ticagrelor under the current economic conditions in China,and can be used as the first selection of antiplatelet therapy for patients after PCI.关键词
吲哚布芬/经皮冠状动脉介入治疗/成本-效用分析/药物经济学Key words
Indobufen/Percutaneous coronary intervention/Cost-effectiveness analysis/Pharmacoeconomics分类
医药卫生引用本文复制引用
弓小雪,杨铭,田硕..吲哚布芬联合替格瑞洛对比阿司匹林联合替格瑞洛用于经皮冠状动脉介入治疗术后的成本-效用分析[J].中国医院用药评价与分析,2023,23(12):1496-1498,1503,4.基金项目
山东省医学会临床科研专项基金项目(No.YXH2019ZX017) （No.YXH2019ZX017）
山东省医务职工科技创新计划项目(No.SDYWZGKCJHLH2023075) （No.SDYWZGKCJHLH2023075）
